['congestive heart failure']
['furosemide injection solution (scp-101)', 'furosemide injection solution, usp']

        Inclusion Criteria:

          -  An Institutional Review Board (IRB) approved informed consent is signed and dated
             prior to any study-related activities.

          -  Male and female subjects > 18 years of age

          -  History of at least 3 months treated heart failure (NYHA class II/III/IV), or recent
             hospitalization for heart failure; presenting to Heart Failure Bridge Clinic (HFBC)
             with decompensated heart failure symptoms including elevated jugular venous pressure,
             dyspnea and peripheral edema where the decision is made to give IV diuretics

          -  Able to participate in the study in the opinion of the investigator

          -  Has the ability to understand the requirements of the study and is willing to comply
             with all study procedures

        Exclusion Criteria:

          -  Presenting with symptoms where it is anticipated that there is a high chance of
             hospitalization such as ischemia, uncontrolled arrhythmia, infection, hemodynamic
             instability (elevated or low blood pressure), respiratory compromise, or electrolyte
             abnormalities (>25% increase in creatinine from baseline, potassium, hyponatremia).

          -  On experimental medication or currently participating in a cardiovascular research
             study.

          -  Presence or need for urinary catheterization, urinary tract abnormality or disorder
             interfering with urination

          -  Any surgical or medical condition which in the opinion of the investigator may
             interfere with participation in the study or which may affect the outcome of the study

          -  Inability to comply with study requirements
      